
usd feb pm et
summari compani global research-bas pharmaceut busi key drug
humira rheumatoid arthriti indic
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
lift target price
base price-to-earnings multipl
combin compani allergan
ep estim ep vs
surpass estim
lower stand-alon ep
initi ep
organ billion humira sale
increas billion
organ million due
oncolog busi grew organ
billion anticip
strong double-digit growth
meanwhil launch skyrizi
rinvoq continu perform well overal
quarter mostli in-lin
expect share trade
substanti past month like
due improv sentiment abbv-agn
merger approach close
heavili reliant one drug humira
current account sale howev
recently-approv drug like help diversifi sale
apr ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview global research-bas biopharmaceut compani
develop market advanc therapi address world complex seriou
diseas product focus treat condit chronic autoimmun diseas
rheumatolog gastroenterolog dermatolog oncolog includ blood cancer virolog includ
hepat viru hcv human immunodefici viru hiv neurolog disord
parkinson diseas metabol diseas includ thyroid diseas complic associ
cystic fibrosi pain associ endometriosi well seriou health condit also
pipelin promis new medicin clinic develop across import medic
specialti immunolog oncolog neurosci addit target invest cystic
fibrosi women health
abbv largest success drug humira approv treat autoimmun diseas
 canada mexico european union humira also sold mani market world-wide
drug account approxim abbv total net revenu humira began
experi biosimilar competit countri outsid ou ou sale account
approxim global humira revenu expect encount biosimilar competit
humira begin possibl earlier anticip entranc biosimilar competit
corpor strategi abbv strategi focus deliv strong financi result advanc
invest pipelin return valu sharehold ensur strong sustain growth
busi long term expect achiev strateg object
hematolog oncolog revenu growth imbruvica venclexta strong execut new
product launch across multipl therapeut area humira sale growth drive biolog
penetr across diseas categori maintain market leadership effect manag
humira intern biosimilar eros favor impact pipelin product indic
recent approv current regulatori review approv expect
pipelin accord abbv form compani compound indic
clinic develop focu immunolog oncolog neurosci abbv program
mid- late-stag develop
impact signific develop june allergan plc enter
definit transact agreement acquir cash stock transact
approxim billion valu premium time transact expect close
earli would creat massiv biopharmaceut compani billion combin
revenu manag expect sharehold see ep accret first full year
combin compani achiev annual pre-tax synergi cost reduct
billion year expect combin compani net debt approxim billion
manag intend reduc billion continu support
dividend growth pipelin invest combin gener billion free cash flow
enough support combin compani capit alloc strategi
financi trend abbv revenu billion increas prior-year period
repres five-year compound annual growth rate compound-annual-growth-rate top-lin growth
larg driven revenu growth relat mavyret imbruvica venclexta continu
strength humira adjust earn per share ep grew year-over-year
repres five-year compound-annual-growth-rate abbv net debt total capit seem high
compani leverag net debt trailing-twelve-month ebitda concern addit
gener billion free cash flow increas prior year
vice chairman extern
oper
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc februari technic indic
bullish
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit outlook biotechnolog
defens sub-industri expect
see ramp-up new drug sale continu
develop mani new innov therapi
declin preval patent
expir anticip
novel fda drug approv
year-over-year record level
partli due govern shutdown earli
year fda approv novel drug
shatter previou record sinc
novel approv set new
drug typic take least five year
reach peak sale level mean
overal biotech industri like see
promis sale growth next year
addit think mani drug
either newli approv late-stag
clinic trial repres major advanc
treatment technolog gene therapi
zolgensma believ cure spinal
muscular atrophi one inject
although deal count
biopharmaceut lower
past decad total deal valu
transact anticip largest
amount sinc accord
evaluatepharma total deal valu driven
coupl mega-d bristol-mey
squibb acquisit celgen
abbvi acquisit botox
manufactur allergan decemb
biotech industri debt level valuat
remain low rel histor level
rel industri lead us
believ continu
favor environ howev
think difficult beat total
deal valu transact
investor interest
biotechnolog stock mute high
drug price intens scrutini
 polit apparatu despit polit
littl happen regulatori
legisl front neg impact
profit biotech firm believ
littl continu achiev politician
address rise health care cost
especi around drug price
impeach proceed novemb
presidenti candid may continu bring
drug price key issu anticip
stock near term think
legisl initi relat drug fall
focu howev presidenti
elect expect drug legisl becom
key area focu legisl
exclus period origin biolog
drug face competit form
biosimilar also typic
manufactur biopharmaceut firm
howev brand biolog manufactur
aggress use patent law
commerci leverag delay
commerci biosimilar
brand biolog maintain market
domin longer result bar
radic regulatori legisl chang
expect biosimilar continu advanc
slowli next sever year
increas driven ralli
compar rise valu
 composit index
declin
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
pm et cfra keep buy opinion share allergan plc
rais target estim valu cash
share mixtur offer today announc agreement
acquir combin would diversifi away drug
humira revenu creat global biopharmaceut firm
term revenu billion annual sale deal troubl
clear regulatori hurdl view see much overlap therapeut
area would surpris see struggl gain approv
sharehold though offer materi premium recent
share price still consider rang sever notabl
hedg fund acquir larg stake sever year ago may push
lucr offer regardless think deal ultim close earli
keep buy rate share see attract upsid remain
deal close /colin scarola
et cfra keep hold opinion share abbvi inc
allergan plc announc morn compani
enter definit transact agreement acquir
cash stock transact approxim billion valu
premium transact expect close earli would
creat massiv biopharmaceut compani billion combin
revenu manag expect sharehold see ep accret
first full year combin compani achiev
annual pre-tax synergi cost reduct billion year
three expect combin compani net debt approxim
billion manag intend reduc billion
continu support dividend growth pipelin invest combin
gener billion free cash flow
enough support combin compani capit alloc strategi
analyst research note compani news
pm et cfra maintain hold opinion share abbvi inc
lift target price base price-to-earnings multipl
combin compani allergan ep estim
ep vs surpass estim lower
stand-alon ep initi ep
revenu increas yoy organ billion
 humira sale increas billion intern humira
net revenu decreas organ million due biosimilar
billion anticip strong double-digit
growth meanwhil launch skyrizi rinvoq
continu perform well overal quarter mostli in-lin
expect share trade substanti past month
like due improv sentiment abbv-agn merger approach close
/kevin huang cfa
pm et cfra keep hold opinion share abbvi inc
lift target base price-to-earnings multipl
combin compani allergan ep estim
ep vs higher estim lift
ep stand-alone ep
sale increas yoy organ billion ahead
consensu expect humira net revenu increas
billion intern humira net revenu decreas
organ billion due biosimilar competit abbv launch
drug skyrizi continu go well sale reach million
million august also announc approv
upadacitinib known rinvoq rheumatoid arthriti
remain track close acquisit satisfi
regulatori concern relat merger intend divest two
agn asset brazikumab zenpep /kevin huang cfa
pm et cfra maintain hold opinion share abbvi inc
lift target base price-to-earnings multipl
combin compani ep estim
ep vs surpass consensu expect lift
ep maintain stand-alone ep
sale declin billion expect due
higher-than-expect sale skyrizi humira outsid ou
ou sale humira continu face biosimilar competit declin
oper vs expect declin meanwhil
sale humira expand billion in-lin expect
skyrizi sale launch may reach million world-wide
expect skyrizi sale exceed million back half
initi expect sale million anticip
posit fda decis come week drug upadacitinib rheumatoid
et cfra keep hold opinion share abbvi inc
lower target price base price-to-earnings multipl
combin compani ep estim combin
compani ep stand-alone ep estim
account pend allergan acquisit merger provid
diversif benefit deriv revenu one
drug humira could also enhanc product portfolio
commerci strength expertis intern infrastructur howev
combin asset two compani like insuffici view
stave sale earn loss attribut expect
entranc biosimilar competit humira addit combin
compani less near-term capac opportunist bolt-on acquisit
billion debt taken fund transact
reason think make sens lower forward price-to-earnings multipl
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
